Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

 The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time.


Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market

It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million individuals are infected with HIV. This has heightened public awareness, which is directing to an increase in testing procedures. This will cause an increase in demand for HIV medicines with greater efficacy for treatment and care over the projected period.

Because of the large percentage of HIV patients in highly populous countries such as China and India, the Asia Pacific market is expected to become the fastest-growing market with the highest CAGR over the coming years. Furthermore, the massive amount of therapeutic interventions, as well as monetary support from corporate companies and medical companies, are anticipated to propel the industry forward.

Key Takeaways from Market Study

  • North America led the market in 2022, with a sales volume of US$ 21 Billion.
  • According to a study conducted by the Centers for Disease Control (CDC) in 2021, an estimated 1.2 million people had HIV at the end of 2018.
  • Based on the World Health Organization (WHO), approximately 33.0 million people were infected with HIV by 2021.
  • Women and girls comprised 54% of all HIV-positive people, according to the WHO.
  • From 2018 to 2022, sales increased significantly at a CAGR of 1.6%.

Key Market Players

 Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc., Boehringer, Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.

  • In July 2021 - Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with the medical company Hetero Labs LTD to make darunavir plus ritonavir (DRV/r) available as a second-line treatment for HIV patients in low and middle-income countries for US$ 210 per patient/year.
  • In March 2021, Gilead Sciences Inc and Merck announced a collaboration agreement to co-develop and co-commercialize long-term HIV treatment. The investigational capsid inhibitor lenacapavir from Gilead and the investigational nucleoside reverse transcriptase translocation inhibitor islatravir from Merck will be paired to form a two-drug HIV regimen.
  • On January 20, 2021 - HIV ViiV Healthcare evolved Cabenuva, an injectable drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus type 1 (HIV) infections in adults.

Acquired Immune Deficiency Syndrome Virus (AIDS virus) is a virus that attacks the immune system of humans, specifically the CD4+ T cells, which play a crucial role in fighting off infections. HIV-1 belongs to the family of retroviruses, which means that it has a unique replication cycle that involves reverse transcription of its RNA genome into DNA and integration into the host cell's genome.

Key Segments Profiled in the Human Immunodeficiency Virus Type 1 (HIV 1) Market Industry Survey

Human Immunodeficiency Virus Type 1 (HIV 1) Market by Drug Class:

  • Nucleoside-Analog Reverse Transcriptase Inhibitor
  • Non-Nucleoside Reverse Transcriptase Inhibitor
  • Entry and Fusion Inhibitors
  • Protease Inhibitors
  • Integrase Inhibitors
  • Coreceptor Antagonists

Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer re...
Read more

Oral Solid Dosage Pharmaceutical Formulation Market is expected to reach US$ 1.0 Billion by 2032

Image
  Demand for the global oral solid dosage pharmaceutical formulation market is anticipated to expand at a robust CAGR of 6.4% over the valuation period from 2022 to 2032. The global market is expected to touch US$ 555.3 Million by 2022 and surpass a valuation of US$ 1.0 Billion in 2032. As per the studies, on the basis of dosage, the tablets segment led to the market with a massive share of around 53.1% in 2021. As per Future Market Insights analysis, the oral solid dosage pharmaceutical formulation market accounted for around 1.4% of the overall US$ 40.0 Billion of the global pharmaceutical drug delivery market in 2021. The expansion of sales of solid dosage pharmaceutical formulations was anticipated at a robust rate of 8.1% from 2012 to 2021, attributed to the surging adoption and greater patient compliance. Get Full Access @ https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market Oral solid dosages are one of the most commonly uti...
Read more